Immunology Sales Specialist ProImmune Inc. Sarasota, Florida
Description: Part 1: In today’s competitive drug market, preclinical immunogenicity risk assessment is critical for success. Gain invaluable insights from real-world case studies that leverage current techniques such as MAPPs, T cell proliferation, MHC-peptide binding, and cytokine release assays. These methodologies are essential for evaluating the immunogenic potential of your drug candidates, ensuring safety and efficacy. Part 2: Understand the current options and context to next-generation target binding reagents that overcome many of the current constraints of research antibodies. This segment delves into the innovative use of animal-free monoclonal binding reagents, which are ten times smaller than conventional antibodies and are based on ankyrin-repeat proteins. These reagents have proven their efficacy across a diverse array of applications, offering high affinity and precision in target protein interrogation. Discover how these advanced tools can provide solutions to previously insurmountable challenges, enhancing your research capabilities and driving forward drug development.
Learning Objectives:
Provide a summary of best-in-class Immunogenicity risk assessment tools with case studies to demonstrate how and when the assays can be incorporated into various therapeutic programs.
Describe a novel animal-free ankyrin-repeat protein binder technology and demonstrate how these tools will address the challenges associated with antibody generation, including customization, cost, timing and requirements of species-specific and isotype controls
Detail in-house and collaborative data to highlight the use in diverse applications, improvements in protocol, advantages in size and achievements in areas that were previously unsuccessful.
.png)
